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Abstract 
Background: Helicobacter pylori infection is a common disease and leads to many gastrointestinal and 
respiratory diseases. It is suspected that one of these respiratory diseases is lung cancer. 
Methods: sixty patients with lung cancer and one hundred twenty control subjects have been included to this 
study. All enrolled subjects (lung cancer patients and controls) underwent a15 minute, lateral flow immunoassay 
for the qualitative detection of IgG antibodies anti-H. Pylori in human serum (CTK Biotech, Inc USA) and a 
lateral immunochromatographic assay for the qualitative detection of H. Pylori antigen in human fecal specimen 
(CTK Biotech,Inc USA) , A p value of <0.05 was considered as significant. The statistical data analysis was 
performed with SPSS 22. . 
Results: The H.pylori seropositivity was (41 /60) (68.3) %in patients with lung cancer but only (16/ 120) (13.3) 
%in controls and this difference in H.pylori seropositivity between cancers and controls was statistically 
significant P<0.016. The odds ratio for the association of H.pylori and lung cancer was 3.6 (95% CI =1.24 – 4.8), 
The H.pylori stool antigen was (22/60) (36.7) % in patients with lung cancer but only (14/120) (11.7) %there is 
statistically significant P<0.001.  
Conclusion increase the prevalence of H.pylori seropositivity was (68.3) %in patients with lung cancer more 
than  in normal controls (13.3) %. 
Introduction 
 The lung cancer is a main health problem with a generally bad prognosis,  It is  one  of  the  most  common 
causes  of  mortality  in  the  world (1,2), It  is  the  commonest cause of cancer death for both male and female 
and accounts for 28% of the overall cancer death rate(3)  The overall incidence of lung cancer has been strongly 
associated to cigarette smoking. It also occurs in association with occupational and environmental exposure to 
carcinogenic agents. There are another factors related to the development of lung cancer such as genetic 
alteration, familial predisposition, and Helicobacter pylori infection (4-6).  
H. pylori (Hp) is Gram-negative , spiral, and has multiple flagella at one end, which make it motile, allowing  it 
to burrow and live beneath the mucus layer adherent  to  the  epithelial  surface. H. pylori use an adhesin 
molecule (BabA) to bind to the Lewis b antigen on epithelial cells.  Here the surface pH is close to neutral and 
any acidity is buffered by the organism’s production of the enzyme urease. H. pylori synthesis ammonia from 
urea and elevate the pH around the bacterium and between its two cell membrane layers. H. pylori mainly 
colonises gastric-type epithelium and exclusively found in the duodenum in association with patches of gastric 
metaplasia.  H. pylori cause chronic gastritis by producing a local inflammatory response in the underlying 
epithelium (7). 
The pathogenesis of H. pylori majorly relay on the producing of several bacterial agents to the host, including 
cytotoxin-associated gene A (CagA), vacuolating cytotoxin A (VacA), type IV secretion system (T4SS), outer 
inflammatory protein A and adherence factors (8). 
Cytotoxins and carcinogenesis-associated proteins of Hp 
The cytotoxin-associated protein (CagA) and the vacuolating   cytotoxin(VacA), are important virulence 
determinants of Hp and may elaborate complex cellular responses of epithelial cells in Hp pathogenesis and 
carcinogenesis (9). Based on the phenotypic analyses of clinical isolates of Hp, more of the strains can be 
classified into two broad groups—those expressing both VacA and CagA (type I) and those producing neither 
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(type II). The remaining Hp strains have an intermediate phenotype (type III), expressing CagA independently of 
VacA (CagA+VacA−) or vice versa (CagA−VacA+) (10).  The CagA gene is located within the Cag pathogenicity 
island region on the bacterial chromosome, which encodes proteins important for structure and function of T4SS 
(11)
. Approximately, 60–70% of Western Hp strains and all of East Asian strains express CagA (12). Many studies 
described that CagA+ strains are closely connected with the development of acute gastritis and pre-malignant 
and malignant lesions (13-15). The relationship between CagA and malignancy were demonstrated in animal 
models (16),supporting strong evidence for the role of CagA as a bacterium-derived oncoprotein VacA, the 
second most extensively studied Hp factor, enhances Hp virulence though its pleiotropic functions in vivo. The 
gene encoding VacA is present in almost all Hp strains (17).There are relationship between VacA and 
gastroduodenal diseases (e.g. peptic ulcer, atrophic gastritis and gastric cancer) (18). The differences in the VacA 
structure at the signal region (s1 and s2) and the middle region (m1 and m2) lead to variations in the vacuolating 
activity (19). Many studies in Western countries showed that individuals infected with VacA s1 or m1 strains have 
an increased risk of peptic ulcer or gastric cancer compared with those with VacA s2 or m2 strains (20, 21). 
Extra gastric manifestations:  
There are strong association between Hp and many abnormal conditions, e.g. cardiovascular (22–24), hematologic 
(25-27)
, eye and skin (28–30) and hepatobiliary diseases (31-33); diabetes mellitus (34–36) and neurological disorders (37–
39)
. And also Hp infection has been associated to be involved in autoimmune pancreatitis and pancreatic cancer 
(40)
, and can increase the risk of transforming growth factor-β1-mediated tumorigenesis by disturbing the balance 
between apoptosis and proliferation of hepatocytes (31). There is also relationship between Hp infection and 
colorectal, laryngeal–hypo pharyngeal malignancy (41, 42). 
Diagnosis    
Different methods of testing exist. One can test noninvasively for H. pylori infection with a blood antibody test, 
stool antigen test, or with the carbon urea breath test (in which the patient drinks 14C— or 13C-labelled urea, 
which the bacterium metabolizes, producing labelled carbon dioxide that can be detected in the breath)(43) Also, a 
urine ELISA test with 96% sensitivity and 79% specificity is available. None of the test methods is completely 
fail safe. Even biopsy is dependent on the location of the biopsy. Blood antibody tests, for example, range from 
76% to 84% sensitivity. Some drugs can affect H. pylori urease activity and give false negatives with the urea-
based tests. The most accurate method for detecting H. pylori infection is with a histological examination from 
two sites after endoscopic biopsy, combined with either a rapid urease test or microbial culture (44).  
Material and Method 
  This study was conducted at the Department of Pulmonary Medicine, of the Baghdad teaching hospital 
Between February 2015 and October 2015, 60 consecutive patients with histologically verified primary lung 
cancer were enrolled in the study.  Lung carcinoma diagnosis was confirmed by fiber optic bronchoscopy and/or 
transthoracic needle aspiration, tru cut biopsy. 
Exclusion  criteria  were:  prior  Helicobacter eradication therapy,  consumption  of  acid  suppressive  drugs, a  
history  of operations  on  the  upper  gastrointestinal tract. The control population included patients hospitalized 
for any other disease other than lung cancer. We selected 120 controls and matched them with the patients for 
sex and age and smoking habit. 
All enrolled subjects (lung cancer patients and controls) underwent a15- minute, lateral flow immunoassay for 
the qualitative detection of IgG antibodies anti-H. Pylori in human serum (CTK Biotech, Inc USA) and a lateral 
immunochromatographic assay for the qualitative detection of H. Pylori antigen in human fecal specimen (CTK 
Biotech,Inc USA)  . 
 Statistical analysis 
The relation between lung cancer and H. pylori infection was assessed by paired t test. All results were compared 
among two groups by percentage and frequency table sand charts. In addition odds ratio (OR) and 95% 
confidence interval were estimated for percentage of lung cancer and H. pylori infection relationship. A p value 
of <0.05 was considered as significant. The statistical data analysis was performed with SPSS 22. 
Results 
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This cross sectional study was carried out in Baghdad teaching hospital a (60) histologically verified 
lung carcinoma patients (42) (70.0%) men and (18) (30.0%) women) with the median age of (57.8±11.4) years 
and (120) controls (44) (36.7%) men and (76) (63.3%) women) with the median age of (42.0±14.1) years .The 
demographic data of both patients and controls are shown in Table 1. 
Table1 the demographic data of the age on both patients and controls  
Statistics 
Age cancer control 
N Valid 60 120 
   
Mean 57.8000 42.0333 
Std. Deviation 
11.44597 14.13259 
 
 
 
Figure 1: frequency of the gender on Cancer patients 
 
 
Table2: the demographic data of gender on  patients  
cancer Frequency 
Valid 
Percent Cumulative Percent 
Valid male 42 70.0                  70.0 
female 18 30.0 100.0 
Total 60 100.0  
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Figure 2-frquency of gender on  control group 
Table3: the demographic data of  gender on  control group 
control Frequency Valid Percent Cumulative Percent 
Valid male 44 36.7 36.7 
female 76 63.3 100.0 
Total 120 100.0  
 
Among  the  lung  cancer  patients,  (34) (56.7 %)  had adenocarcinoma,  (26)  (43.3 %)  had  squamous  cell 
carcinoma, see table 4 
Table 4: frequency of histological type cancer 
 
Histological type Frequency Valid Percent 
Cumulative 
Percent 
Valid squamous ca 26 43.3 43.3 
adenocarcinoma 34 56.7 100.0 
Total 60 100.0  
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 The prevalence of H.pylori seropositivity was (41 /60) (68.3) %in patients with lung cancer but only (16/ 120) 
(13.3) %in controls and this difference in H.pylori seropositivity between cancers and controls was statistically 
significant P<0.016. The odds ratio for the association of H.pylori and lung cancer was 3.6 (95% CI =1.24 – 4.8,) 
see table5 Characteristics of patient group and control group, and also the figure 3,4,5,6 revealed the differences 
in level of antigens and antibodies in control and lung cancer patients    
 
 
Figure 3: the level of antibodies in lung cancer pateints  
 
Table5: Characteristics of patient group and control group 
 
 Cancer  normal P value 
H. pylori Ab 
positive 
41 (60) 
(68.3)% 
16 (120) 
(13.3)% 
0.016 
H. pylori Ag 
positive 
22(60) 
(36.7)% 
14(120) 
(11.7)% 
0.001 
Age(year) 57.8± 11.4 42± 14.1 0.244 
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Figure 4: the level of antigen in lung cancer pateints  
 
 
Figure 5: the level of antibodies in control group  
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Figure 6: the level of antigen in control group  
 
 
Discussion 
H. pylori has become a world-wide infective agent ranging from 25% in developed countries to more 
than 80% in the developing world (45). H. pylori infection has an important role in the development of chronic 
gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue (MALTlymphoma), and gastric cancer (46-49).In 
our study; H. pylori seropositivity was significantly higher in cancer patients than in control subjects. Also more 
lung cancer cases were stool antigen positive patients than controls. Previous studies investigated the association 
between H. pyloriseropositivity and lung cancer. Ece et al, found a 93% seroprevalence of antibodies against  H. 
pylori in  40  consecutive  patients with  lung  cancer  and  a  42% seroprevalence in 12 control subjects(50). Ferah 
Ece et al, study reported that CagA strain seropositivity inblung cancer patients was about thrice as high as in 
controls (63% vs. 21.5%, respectively, P≤0:05) (51) 
Roussos et al, found a significant association between chronic bronchitis and H. pylori (52) 
The  results  of  previous  study  showed  that  the  population of patients  with  lung  cancer  has  a  significantly  
higher  rate  of seropositivity for antibodies against  H.pylori (48 of 66) than the  population  of  subjects  
without  lung  cancer  (34  of  66). (OR=2.51, 95%CI= 1.14 – 5.54    P<0.05). (53) 
Gocyk et al (54) they demonstrated a significantly higher H pylori seroprevalence among patients with lung 
cancer in comparison with healthy subjects (89.5% vs64% respectively, P< 0.05). 
Lungs arise embriologically from the same endodermal cells that form the lining of the gastrointestinal tract and 
possess similar cells releasing various hormonal peptides. (55) 
Lung cancer patients were characterized by a significant increase of gastrin concentration in both serum and 
Broncho alveolar lavage (BAL). They also demonstrated that m-RNA expression for gastrin and its receptor, as 
well as for cyclooxygenase (COX)-2, is enhanced in the tumor tissue. Increased plasma level of gastrin which is 
accompanied by H. pylori infection may contribute to the lung cancerogenesis by inducing mucosal cell 
proliferation of bronchial epithelium. (56, 57) 
Zhou et al. (58) it has been shown that serum from patients with lung cancer contained a high concentration of 
gastrin, and serum gastrin was found to decrease gradually after the removal of the tumor and to return to normal 
on the 14th postoperative day. 
H. pylori infection is accompanied by an increased plasma level of gastrin, suggesting that this hormone could 
contribute to  the  lung  carcinogenesis  by  inducing  higher  mucosal  cell proliferation  of  bronchial  
epithelium  leading  to  atrophy  and induction of COX-2(59,60) . This finding that lung cancers exhibit higher 
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expression and content of gastrin and its receptors is akin  to   up  regulation  of  gastrin  biosynthesis  already 
described  for  gastric  cancers  and  colorectal  cancers(61) . 
Reason for the increased risk of lung cancer in H. pylori infected patients can be explained in several ways. (i) H. 
pylori is Gram-negative bacteria with lipopolysaccharideas the major component of the cell wall. 
Lipopolysaccharide stimulates the production of proinflammatory cytokinesIncluding interleukins and tumor 
necrosis factor-alpha (62). This leads to chronic inflammation and immune stimulation, which may contribute to 
carcinogenesis (63, 64, and 65). (ii) The lungs arise embryological from the same endoderm cells that form the lining 
of the gastrointestinal tract and possess, similar neuroendocrine and paracrine cells releasing various hormonal 
peptides and their receptors including gastrin releasing peptide and gastrin (66, 67). 
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